Free Newsletter
Genetics research offers new life to failed drugs
Big Pharma companies are often quick to turn their backs on a drug that doesn't deliver the kind of data needed to win approval as well as big markets. But a series of these failed development programs have been resurrected by scientists who decided to search for the kind of genetic biomarkers that would define a group of patients who would respond positively.
Research scientist Michael Bristow, for example, has formed a new company to take over development of bucindolol, which had failed to measure up against other cardiovascular drugs on the market. And Clinical Data hopes that it can identify a subpopulation of patients who will respond to the antidepressant vilazodone, dropped after a disappointing mid-stage trial mounted by Merck KGaA.
- read the article in the Wall Street Journal
Related Articles:
Clinical Data upbeat on antidepressant. Report
Gene Logic takes fresh look at Merck KGaA drugs. Report
Biomarker company gains $25M in fresh backing. Report
Comments
By Jeong Chun Phuoc | Posted 11:12am | March 25, 2008
25.3.2008 "CHANNELING UNSUCCESSFUL DRUGS FOR OTHER MEDICAL USES" Developed pharma drugs that do not delivered or achieved projected commercial results should not be put to waste. These drugs could be for other secondary medical purposes in other area of genetic research. It could also be channeled towards 'orphan drugs collection' to treat other medical/genetic symptoms of public interest. This will ensure that pharma-companies play both role as inventor of new drugs and at the same time fulfill their corporate social responsibility. It's a win-win situation for both the pharma-companies and the public at large.
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FierceBiotech Research email newsletter for FREE!
Comments (1) | Post a comment